Inclusion Criteria

-INCLUSION CRITERIA:

1. All patients with stage IV ocular melanoma, who have measurable disease will be
considered.

2. Patients must have histopathological documentation of ocular melanoma confirmed in
the Laboratory of Pathology/National Cancer Institute (NCI) of the Clinical Center at
the National Institutes of Health. This can be from tissue obtained outside the
National Institutes of Health (NIH).

3. Patient must be Eastern Cooperative Oncology Group (ECOG) performance status of less
than or equal to 2.

4. Patients must have a life expectancy of more than 3 months.

5. Hematological eligibility parameters (prescreen):

- Granulocyte count greater than 1,500/mm^3

- Platelet count greater than 100,000/mm^3

- If the creatinine is greater than 1.5 mg/dL, obtain a 24 hour urine collection.
Creatinine clearance must be greater than 60 mL/min/1.73m^2.

- Hepatic function: bilirubin (total) less than or equal to 2.0 mg/dl; Alanine
aminotransferase (ALT) less than 10 x upper limit of normal; Aspartate
aminotransferase (AST) less than 10 x upper limit of normal.

6. Patients must have recovered from any acute toxicity related to prior therapy or
surgery, to a grade 1 or less unless specified above.

7. Patients must not have had prior surgery, chemotherapy, hormonal therapy, radiation
therapy, or biological therapy, for at least 4 weeks prior to starting study
medication. Patients who were receiving mitomycin C, nitrosoureas, or carboplatin
must be 6 weeks from the last administration of chemotherapy.

8. Patients must not have an acute, critical illness, including a serious untreated
infection.

9. Patients must be willing to return to the National Institutes of Health (NIH) for
follow-up visits.

10. All patients who are sexually active and able to conceive will be required to use
contraception during treatment with lenalidomide.

Only two criteria are allowed by the Food and Drug Administration (FDA) for the status of
not of child bearing potential: hysterectomy or menopause for 24 consecutive months. Women
of child bearing potential will be required to use two methods of birth control, one
highly effective method and one additional method, at the same time during treatment and
for one month after the completion of lenalidomide treatment. These methods must be used
for at least four weeks before starting lenalidomide, during treatment, and for at least
four weeks following the last dose of lenalidomide. Acceptable forms of birth control
include:

Intrauterine device (IUD)

Latex condom

Hormonal (Birth control pills, injections, implants)

Diaphragm

Tubal Ligation

Cervical cap

Partner's vasectomy

Two barrier methods may be used if the physician agrees that the highly effective methods
are medically contraindicated.

Women of childbearing potential must have a negative urine pregnancy test 24 hours prior
to the start of lenalidomide.

Men who are sexually active must agree to use latex condoms.

Patients must be able to understand and sign informed consent form.

Patients must be greater than or equal to 18 years of age.

EXCLUSION CRITERIA:

1. Patients with evidence of active brain metastases will be excluded. Patients must
have had a complete excision or radiotherapy and remain asymptomatic with stable
disease as shown by magnetic resonance imaging (MRI) for at least six months.

2. Patients who are pregnant or lactating. No data is currently available about the
excretion of lenalidomide in breast milk. Although no preclinical data suggest
teratogenicity with this compound, because of the relationship to thalidomide, we
will exclude patients who are pregnant or lactating.

3. Patients with a history of unstable or newly diagnosed angina pectoris, recent
myocardial infarction (within 6 months of enrollment), New York class II-IV
congestive heart failure, chronic obstructive lung disease requiring oxygen therapy
or uncontrolled seizure activity are not eligible.

4. Patients who are known positive for human immunodeficiency virus (HIV) as it may
increase their risk of infection since lenalidomide has effects on cells involved in
the immune system.

5. Patients who have had prior therapy with lenalidomide.

6. Patients with known hypersensitivity reaction to lenalidomide.